CureVac cuts jobs, licenses out vaccines to GSK
BioPharma Drive: Drug Pricing
JULY 3, 2024
The mRNA specialist plans to eliminate 30% of its workforce as part of a restructuring that will prioritize “high-value” projects like its cancer vaccines.
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
BioPharma Drive: Drug Pricing
MAY 13, 2024
The deal — worth $100 million up front and potentially billions more later on — gives Takeda an exclusive option to license an Alzheimer’s vaccine and other “active immunotherapies.”
Licensing 
78
78 
Touchlight signs patent license agreement with Pfizer for the use of dbDNA for the manufacture of mRNA-based vaccines, therapeutics and gene therapies
Drug Discovery Today
JULY 7, 2022
Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer’s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapiesAgreement includes upfront payment, potential development and commercial milestone payments, and royalties upon commercializationAccess (..)
Licensing 100
100 
Eyam Vaccines and Immunotherapeutics Reaches Agreement to License Next-Generation COVID-19 Vaccine Candidates from the University of British Columbia
The Pharma Data
DECEMBER 2, 2020
This License Agreement represents an important corporate milestone. The License provides EYAM with the exclusive right to develop several proprietary COVID-19 vaccine candidates in a self-amplifying mRNA vaccine platform. EYAM anticipates rapid commencement of animal trials for these COVID-19 vaccine candidates.
Licensing 52
52 
Swiss startup LimmaTech licenses GSK vaccine, hires ex-CureVac chief as CEO
BioPharma Drive: Drug Pricing
JULY 20, 2023
The startup will take on development of a shigellosis vaccine GSK inherited when it acquired LimmaTech’s predecessor, GlycoVaxyn, in 2015.
Vaccine 52
52 
Article FDA Thank You Vaccines advisory panel endorses move to trivalent formulation for U.S. flu vaccines
Agency IQ
MARCH 7, 2024
Vaccines advisory panel endorses move to trivalent formulation for U.S. flu vaccines Yesterday, FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) weighed in on strains for seasonal influenza vaccines for the Northern hemisphere 2024-2025 season.
Vaccine 40
40 
Targovax grants IOVaxis 3 months extension to the exclusive license option for TG mutant RAS vaccines in Greater China and Singapore
The Pharma Data
JANUARY 5, 2021
Due to the unforeseen delays, Targovax has extended the term of IOvaxis’s license option by 3 months, otherwise the agreement remains unchanged. To accommodate the delay caused by these unforeseen circumstances, Targovax has granted to IOVaxis an extension to the license option period by 3 months.
Licensing 40
40 
Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of COMIRNATY® in Adolescents 12 Through 15 Years of Age
The Pharma Data
MAY 6, 2022
NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the approval of COMIRNATY® (COVID-19 Vaccine, mRNA) to include individuals ages 12 through 15 years. Pfizer Inc.
FDA Approval 52
52 
WHO and Partners to Stockpile Ebola Vaccine
The Pharma Data
JANUARY 12, 2021
WHO and Partners to Stockpile Ebola Vaccine. 12, 2021 — Ebola vaccines are being stockpiled by the World Health Organization and other groups to combat future outbreaks of the deadly disease. Professional. TUESDAY, Jan. Nearly 7,000 doses are currently available. Associated Press Article. © 2021 HealthDay.
Vaccine 52
52 
COVID-19 nasal vaccine candidate effective at preventing disease transmission
The Pharma Data
SEPTEMBER 30, 2021
Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. A fundamental limitation of intramuscular vaccines is that they’re not designed to elicit mucosal immunity.
Vaccine 52
52 
Coronavirus vaccine: UK signs deals for 90 million virus vaccine doses
The Pharma Data
AUGUST 13, 2020
The UK government has signed deals for a further 90 million doses of coronavirus vaccine. The vaccines are being developed by the Belgian pharmaceutical company Janssen and the US biotech company Novavax. It means the UK has placed orders for six experimental vaccines, taking its potential stockpile to 340 million doses.
Vaccine 52
52 
Update on the safety of COVID-19 Vaccine AstraZeneca
The Pharma Data
MARCH 14, 2021
Following a recent concern raised around thrombotic events, AstraZeneca would like to offer its reassurance on the safety of its COVID-19 vaccine based on clear scientific evidence. Safety is of paramount importance and the Company is continually monitoring the safety of its vaccine. COVID-19 Vaccine AstraZeneca , formerly AZD1222.
Vaccine 52
52 
CEPI to Fund Late-Stage COVID-19 Vaccine Trial From Clover Biopharmaceuticals | 2020-11-03
The Pharma Data
NOVEMBER 3, 2020
The Coalition for Epidemic Preparedness Innovations (CEPI) has agreed to fund development of a potential COVID-19 vaccine from China’s Clover Biopharmaceuticals with a global phase 2/3 study and through licensing and distribution. million investment announced in July. Earlier this year, CEPI provided $3.5
Vaccine 52
52 
U.S. FDA APPROVES TICOVAC™, PFIZER’S TICK-BORNE ENCEPHALITIS (TBE) VACCINE
The Pharma Data
AUGUST 15, 2021
Food and Drug Administration (FDA) has approved TICOVAC (tick-borne encephalitis (TBE) vaccine) for active immunization to prevent TBE in individuals 1 year of age and older. 1 TICOVAC is the only FDA-approved vaccine to help protect U.S. We are proud to deliver the first vaccine to help protect people in the U.S. 45 years ago.
FDA Approval 52
52 
U.S. CDC Advisory Committee on Immunization Practices Recommends Vaccination with Moderna’s COVID-19 Vaccine for Persons 18 Years and Older
The Pharma Data
DECEMBER 19, 2020
Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. 11 ACIP members voted in favor of the vaccine and 0 members voted against. We look forward to vaccinations of this important population starting this week.”. .–( BUSINESS WIRE )– Moderna, Inc.,
Vaccine 52
52 
COVID-19 Vaccinations – Where a Commitment to Diversity is Essential
Eye on FDA
DECEMBER 1, 2020
In my last posting on preparedness for a post-vaccination world I touched on some of the questions facing employers in general – policy questions that should be considered now for the eventualities of later. COVID-19 has cast a particularly harsh light on this fact where minorities in the U.S.
Vaccine 66
66 
First ever vaccine listed under WHO emergency use
The Pharma Data
NOVEMBER 13, 2020
WHO today listed the nOPV2 vaccine (Bio Farma, Indonesia) for emergency use to address the rising cases of a vaccine-derived polio strain in a number of African and East Mediterranean countries. The emergency use listing, or EUL, is the first of its kind for a vaccine and paves the way for potential listing of COVID-19 vaccines.
Vaccine 52
52 
AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development
The Pharma Data
JANUARY 11, 2021
a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.
Licensing 52
52 
First Single-Shot Vaccine in Fight Against Global Pandemic
The Pharma Data
MARCH 2, 2021
Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. The terms of the EUA allow use of the vaccine while more data are gathered.
Vaccine 52
52 
Johnson & Johnson Statement on COVID-19 Vaccine (7/12)
The Pharma Data
JULY 12, 2021
Rare cases of the neurological disorder, Guillain-Barré syndrome have been reported following vaccination with the Janssen COVID-19 vaccine. Most occurred within 42 days after vaccination. For further information on the safety of authorized COVID-19 vaccines, please visit: [link]. What Is the Janssen COVID-19 Vaccine?
Vaccine 52
52 
Novavax inks deal to deliver one billion COVID-19 vaccine doses in India and other regions
The Pharma Data
AUGUST 10, 2020
Novavax is partnering up with the Serum Institute of India Private Limited (SIIPL) in a licensing deal to development and marketing of up to one billion doses of its potential recombinant COVID-19 vaccine candidate, NVX?CoV2373. Negotiations are currently ongoing to have SIIPL manufacture the candidate within India. M adjuvant.
Vaccine 52
52 
Retired Doctors, Nurses Will Be Approved to Give COVID-19 Vaccine, White House Says
The Pharma Data
JANUARY 27, 2021
Retired Doctors, Nurses Will Be Approved to Give COVID-19 Vaccine, White House Says. COVID-19 vaccination effort, the White House COVID-19 Response team announced Wednesday. Professional. WEDNESDAY, Jan. 27, 2021 — Retired doctors and nurses are being called to the front lines of the U.S. 26, said Rochelle Walensky, M.D.,
Nurses 52
52 
Coronavirus: Health workers' army to be trained to deliver Covid vaccine
The Pharma Data
AUGUST 28, 2020
The government plans to train up an army of health professionals to be ready to give the coronavirus vaccine, if and when one is shown to work. This could include pharmacists, who already deliver flu vaccines, midwives and physiotherapists. But a vaccine is not expected to be ready before Christmas. Source link.
Vaccine 52
52 
Two billion doses of AstraZeneca’s COVID-19 vaccine supplied to countries across the world
The Pharma Data
NOVEMBER 17, 2021
AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the last 11 months. 2) From the body of evidence in clinical trials and real-world data, the vaccine has been shown to have an acceptable safety profile.(3,4,5,6,7).
Vaccine 52
52 
PFIZER AND THE MEDICINES PATENT POOL (MPP) SIGN LICENSING AGREEMENT FOR COVID-19 ORAL ANTIVIRAL TREATMENT CANDIDATE TO EXPAND ACCESS IN LOW- AND MIDDLE-INCOME COUNTRIES
The Pharma Data
NOVEMBER 17, 2021
The agreement will enable MPP to grease fresh product and distribution of the investigational antiviral, pending nonsupervisory authorization or blessing, by grantingsub-licenses to good general drug manufacturers, with the thing of easing lesser access to the global population. This press release features multimedia.
Licensing 52
52 
Keeping tabs on Covid-19: UK firm tests oral delivery of Covid-19 vaccine and Novavax aims to distribute 51 million vaccines to Australia
The Pharma Data
JANUARY 22, 2021
As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.
Vaccine 52
52 
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
The Pharma Data
MARCH 11, 2021
Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.
First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.
The Pharma Data
MARCH 2, 2021
Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. “For
Vaccine 52
52 
AstraZeneca takes COVID-19 vaccine to China with BioKangtai deal for 200M-dose capacity by 2021
The Pharma Data
AUGUST 6, 2020
We pointed out last week that China was a notable missing element in AstraZeneca’s COVID-19 vaccine strategy, despite being the drugmaker’s second-largest market. The pair will also explore the possibility of producing the vaccine for other markets. The vaccine was moved into phase 2/3 in May. That has changed.
Vaccine 52
52 
FDA Will Follow The Science On COVID-19 Vaccines For Young Children
The Pharma Data
SEPTEMBER 28, 2021
Many parents have questions on COVID-19 and when vaccines are going to be available for youngsters younger than 12 years aged. We are therefore also wanting to see COVID-19 vaccines available for young children. Some have stated that they’re still enrolling, and a few are still administering doses or following participants.
Vaccine 52
52 
Operation Warp Speed’s top doctor says coronavirus vaccine likely won’t be approved until after November
The Pharma Data
SEPTEMBER 4, 2020
Dr Moncef Slaoui, the leading doctor involved with Operation Warp Speed, has said it is unlikely a vaccine for the US will be ready by November. . But Slaoui did say that he believes a vaccine will be available by the end of the year, and could possibly vaccinate between 20 and 25 million people.
Doctors 52
52 
Women in STEM with Kristina Torfgard
Drug Target Review
SEPTEMBER 5, 2024
This role gave me a good understanding of how important IP/patent and global marketing are for the brand but also the importance of emerging markets and co-development and out-licensing to other pharma companies. I got the opportunity to lead a biopharma company at Alzinova that are developing a vaccine candidate against Alzheimer’s disease.
Pharma Companies 111
111 
Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine
The Pharma Data
JUNE 26, 2021
Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021. We look forward to sharing initial results by year-end. ”. “
Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development
The Pharma Data
AUGUST 3, 2021
Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas Fast tracks establishment of Sanofi’s recently announced mRNA Center of Excellence Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technology.
Vaccine 52
52 
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan
The Pharma Data
APRIL 18, 2022
Takeda today announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for Nuvaxovid ® Intramuscular Injection (Nuvaxovid), a novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization in individuals aged 18 and older.
Vaccine 52
52 
BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE INNOVATIVE ANTIBODIES FROM A*STAR FOR TARGETED CANCER THERAPIES
The Pharma Data
JUNE 2, 2022
Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.
Licensing 52
52 
Asia-Pacific Roundup: New Zealand bans unapproved COVID vaccines
The Pharma Data
MAY 4, 2021
The New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has banned the trade in unapproved COVID-19 vaccines for a year to prevent the use of vaccines that may not be safe or effective. . The public could also import personal supplies of vaccines. Medsafe framed the action in the context of public safety. . “In
Vaccine 52
52 
Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure
The Pharma Data
JANUARY 31, 2021
Gilead and Gritstone will develop an HIV-specific therapeutic vaccine using Gritstone’s proprietary prime-boost vaccine platform, comprised of self-amplifying mRNA (SAM) and adenoviral vectors, with antigens developed by Gilead. This press release features multimedia. View the full release here: [link].
Vaccine 52
52 
Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine
The Pharma Data
APRIL 1, 2021
Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine. Sanofi announces investment of more than €600 million to build a new vaccine facility in Toronto to increase supply of its differentiated influenza vaccines in Canada, the United States and Europe.
Vaccine 52
52 
Merkin Prize in Biomedical Technology awarded to F. William Studier for development of widely used protein- and RNA-production platform
Broad Institute
MAY 14, 2024
The approach has been used to produce numerous therapeutics, diagnostics, and vaccines — including the COVID-19 mRNA vaccines credited with extending millions of lives in recent years. “F. In 2020, scientists used the T7 platform to produce enough mRNA for COVID-19 vaccines to vaccinate millions of people in the U.S.
RNA 84
84 
Pfizer and BioNTech Receive Positive CHMP Opinion for COVID-19 Vaccine Booster in Adolescents 12 through 17 Years of Age in the European Union
The Pharma Data
FEBRUARY 24, 2022
If the EC grants the variation, the decision will be immediately applicable to all 27 EU member states, making booster vaccines available to everyone 12 years and older. . The COVID-19 vaccine booster for individuals 12 through 15 years of age was already granted Emergency Use Authorization by the U.S. and Europe.
Vaccine 52
52 
Details of Adverse Event in AstraZeneca’s Vaccine Trial Still Unknown | 2020-10-15
The Pharma Data
OCTOBER 15, 2020
More than a month has passed since AstraZeneca’s phase 3 COVID-19 vaccine trial was paused due to a potential adverse event, but few solid details have emerged from ongoing safety reviews by the FDA and the UK drugmaker. The vaccine trial, which has resumed in other countries but remains halted in the U.S., The length of time the U.S.
Vaccine 52
52 
Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial
The Pharma Data
SEPTEMBER 12, 2020
Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced today that they have submitted an amended protocol to the U.S.
Vaccine 52
52 
Johnson & Johnson Single-Shot COVID-19 Vaccinations to Resume in the U.S. for All Adults Aged 18 and Older Following CDC and FDA Decision
The Pharma Data
MAY 8, 2021
Johnson & Johnson (NYSE: JNJ) (the Company) today announced that vaccinations with the Company’s COVID-19 single-shot vaccine will resume for all adults aged 18 years and older in the U.S., The vaccine showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination.
Vaccine 52
52 
Let's personalize your content